PhI­II dead end for celi­ac drug crush­es pen­ny stock biotech

A com­pound that’s been tout­ed as the first-ever drug to en­ter a Phase III tri­al for celi­ac dis­ease ap­pears to have run in­to a dead end.

At an in­ter­im sta­tis­ti­cal analy­sis de­signed to de­ter­mine how many more pa­tients it would take to de­tect a sta­tis­ti­cal­ly sig­nif­i­cant ef­fect of lara­zotide, 9 Me­ters Bio­phar­ma said it may have to shut­ter the study be­cause “the ad­di­tion­al num­ber of pa­tients need­ed to de­ter­mine a sig­nif­i­cant clin­i­cal out­come be­tween place­bo and lara­zotide is too large to sup­port tri­al con­tin­u­a­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER